Thursday, December 4, 2014

Spotlight Innovation Inc. (OTCQB: STLT) announces that a request was submitted to the Center for Drug Evaluation and Research at the Food and Drug Administration to reactivate and transfer the Celtic Biotech (Ireland) National Drug Code (NDC) registration to Celtic Biotech Iowa Inc. in anticipation of the manufacture and commercialization of a proprietary transdermal delivery gel product. The novel gel formula, originally developed by scientists at Celtic Biotech to facilitate the topical delivery of its proprietary biologic analgesic and anti-inflammatory drugs, is designed to provide a convenient platform for the compounding pharmacy industry to prepare and effectively deliver topical pain medications.

No comments: